

Elasomeran/tozinameran**Anaphylaxis and vertigo: 3 case reports**

In a retrospective review of 12 patients, 3 women aged 54–63 years were described, who developed anaphylaxis or vertigo following vaccination with tozinameran or elasomeran [routes and dosages not stated; not all duration of treatments to reaction onsets and outcomes stated].

A 63-year-old woman presented with tachycardia, hypertension, near-syncope, sense of impending doom, diaphoresis, palpitations, dizziness and pruritic urticaria all over her neck and chest; developed after 35 minutes of vaccination with tozinameran [Pfizer COVID-19 vaccine]. Her medical history was significant for anaphylaxis to unspecified penicillins as a teenager. At current presentation, a diagnosis of grade-3 anaphylaxis secondary to tozinameran was confirmed. Treatment was initiated with unspecified corticosteroids and antihistamines. Thereafter, her symptoms showed resolution within an hour. After 9 hours of vaccination, she developed diarrhoea and abdominal cramping. An allergy skin test to polyethylene glycol (PEG) and polysorbate (PS) tested negative. She received the second vaccination dose with Ad26.COV2-S [Johnson & Johnson vaccine] and showed no complications.

A 60-year-old woman presented with globus sensation in throat, dizziness, mild lip angioedema and pruritic urticaria on her cheeks; developed after 40 minutes of vaccination with tozinameran [Pfizer COVID-19 vaccine]. A diagnosis of grade-1 anaphylaxis secondary to tozinameran was confirmed. She administered unspecified antihistamines and the symptoms showed resolution within an hour. An allergy skin test to PEG and PS tested negative. In the past, she had experienced a similar globus sensation. She then received her second tozinameran dose, without any complications.

A 54-year-old woman with a medical history of recurrent idiopathic anaphylaxis, underwent vaccination with elasomeran [Moderna vaccine]. She developed vertigo for 48 hours secondary to the second dose of elasomeran.

Carpenter T, et al. Polyethylene glycol and polysorbate testing in 12 patients before or after coronavirus disease 2019 vaccine administration. *Annals of Allergy, Asthma and Immunology* 128: 99-101, No. 1, Jan 2022. Available from: URL: <http://www.elsevier.com/wps/find/journaldescription.reviewers/722283/description#description> 803671081